Xiangmin Cui Net Worth

Track Major Insider Updates On X/Twitter

Last Updated: 2 months, 2 weeks ago

Xiangmin Cui has an estimated net worth of at least $92.3 million*, as of Oct. 29, 2025. They own 17.1 million shares of NUVB stock. They have sold 0 shares of NUVB stock since 2021, for an estimated $-1.5 million.

Xiangmin Cui $NUVB SEC Form 4 Insider Trading

Xiangmin Cui has filed a total of 3 insider trades in $NUVB since 2021. Their most recent trade was a purchase of 87,715 shares, made on Jun 20, 2024. Their largest trade was a purchase of 336,874 shares, made on Jun 24, 2024. We estimate that they now own 17.1 million shares of $NUVB, worth an estimated $93.8 million.

Insider Trading at $NUVB

There have been a total of 46 insider trades reported at $NUVB since 2021, with 7.8 million shares purchased and 7.9 million shares sold. The most active insider traders in $NUVB stock have been Dongfang Liu, David Hung, and Gary Hattersley. The most recent trade was a sale of 150,000 shares reported by Dongfang Liu (CHIEF MEDICAL OFFICER), made on Dec 01, 2025.

History of Insider Stock Trades by Xiangmin Cui

Company Ticker	Purchase / Sale	Shares	Date	Disclosed (EST)
NUVB	Purchase	87,715	Jun 20, 2024	June 25, 2024, 5:45 p.m.
NUVB	Purchase	75,411	Jun 21, 2024	June 25, 2024, 5:45 p.m.
NUVB	Purchase	336,874	Jun 24, 2024	June 25, 2024, 5:45 p.m.
ALPN	Purchase	1.5 million	Sep 17, 2021	Sept. 20, 2021, 8 p.m.

$NUVB Executives and Stock Owners with Insider Trades

Dongfang Liu, CHIEF MEDICAL OFFICER
David Hung, PRESIDENT AND CEO
Gary Hattersley, CHIEF SCIENTIFIC OFFICER
Kerry Wentworth, CHIEF REGULATORY OFFICER
Philippe Sauvage, Chief Financial Officer
Colleen Sjogren, Chief Commercial Officer
David C. Hanley, CHIEF TECHNICAL OPERATIONS
Junyuan Jerry Wang, CEO, ANHEART THERAPEUTICS LTD.
Stacy Markel, CHIEF PEOPLE OFFICER

*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.